DXCM vs SNY
Dexcom vs Sanofi — AI-powered side-by-side comparison
| Metric | DXCM | SNY |
|---|
| AI Score |
65
|
66
|
| Price |
$89.16
|
$46.00
|
| P/E Ratio |
35.16×
|
24.00×
|
| ROE |
30.5%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
62.5%
|
72.8%
|
| Debt / Equity |
0.53×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.3%
|
| RSI (14) |
65.4
|
67.8
|
| Beta |
1.41
|
0.278
|
| Expected Upside |
+2.3%
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for DXCM versus SNY.
SNY leads by 1 points.
SNY scores 66/100 (Buy) versus DXCM at 65/100 (Buy).
DXCM Committee View
67% agreement
6 analysts
The primary driver is eps growing 79.4% yoy. The main limiting factor is p/e of 34.5 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is eps declining -37.4% yoy despite any revenue growth. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 4.1% pays you to wait — Value
- Revenue growing 39.5% YoY -- genuine top-line momentum — Growth
Bear Case
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth